Mumbai, July 29: J B Chemicals & Pharmaceuticals Ltd has received approval from Drugs Controllers General of India to market "Rantac CD" (Ranitidine) formulations in India, making it the first entity in the country to get this permission. "Rantac CD" is indicated for the treatment of Gastro Esophageal reflux disorder (GERD) and it would be marketed in 150 and 300 mgs dosage forms, the company said in a release here today and added the current market size of Ranitidine-based formulations in India was approximately Rs 150 crore.

The company was also in the process of filing the necessary application claiming exemption from price control, it said.
JB Chemicals said Rantac CD was the company's second largest brand and its sales for fiscal 2002-03 amounted to around Rs 23 crore, which comes to nine per cent of total sales.
Manufactured at Panoli plan, Gujarat, the company currently holds patents for Ranitidine in the US, South Africa and India. Bureau Report